Beacon Biosignals
Provides AI-powered EEG monitoring and analytics for brain health.
Company facts
- Founded
- 2019
- Employees
- 112
- Headquarters
- United States
- CEO
- Jacob Donoghue, MD PhD
- Type
- Private
- Funding
- Series B · $86M · 2025
- Subsidiaries
- CleveMed
About
Beacon Biosignals is a pioneering company that focuses on powering precision medicine for the brain. Their innovative EEG neurobiomarker platform is instrumental in accelerating clinical trials, enabling new treatments for patients battling neurological and psychiatric diseases. At the core of their efforts lies a drive to enhance the understanding, diagnosis, and treatment of these conditions through advanced brain analytics and machine learning methodologies. Beacon’s unique approach combines FDA-cleared EEG devices and state-of-the-art algorithms that harness the power of extensive datasets to provide insights and analyses previously unattainable in clinical settings. By facilitating data collection that is both lab-quality and home-based, Beacon is changing how researchers and practitioners understand treatment efficacy, improve patient stratification, and optimize clinical trials' success rates. Their dedication to building partnerships with biopharma companies, neurotechnology developers, and academic institutions underscores a commitment to redefining patient care and transforming lives through actionable insights and innovative technologies.